Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Benitec Biopharma's Operating Expenses history spans 7 years, with the latest figure at $10.2 million for Q1 2025.

  • For Q1 2025, Operating Expenses rose 146.03% year-over-year to $10.2 million; the TTM value through Mar 2025 reached $32.3 million, up 50.39%, while the annual FY2024 figure was $22.5 million, 17.4% up from the prior year.
  • Operating Expenses for Q1 2025 was $10.2 million at Benitec Biopharma, down from $10.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $10.8 million in Q4 2024 and bottomed at $3.5 million in Q1 2022.
  • The 5-year median for Operating Expenses is $4.8 million (2021), against an average of $5.5 million.
  • The largest annual shift saw Operating Expenses dropped 7.56% in 2022 before it soared 146.03% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $4.9 million in 2021, then increased by 15.72% to $5.6 million in 2022, then rose by 23.17% to $6.9 million in 2023, then soared by 55.98% to $10.8 million in 2024, then fell by 5.71% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Operating Expenses are $10.2 million (Q1 2025), $10.8 million (Q4 2024), and $5.8 million (Q3 2024).